<code id='42499B08ED'></code><style id='42499B08ED'></style>
    • <acronym id='42499B08ED'></acronym>
      <center id='42499B08ED'><center id='42499B08ED'><tfoot id='42499B08ED'></tfoot></center><abbr id='42499B08ED'><dir id='42499B08ED'><tfoot id='42499B08ED'></tfoot><noframes id='42499B08ED'>

    • <optgroup id='42499B08ED'><strike id='42499B08ED'><sup id='42499B08ED'></sup></strike><code id='42499B08ED'></code></optgroup>
        1. <b id='42499B08ED'><label id='42499B08ED'><select id='42499B08ED'><dt id='42499B08ED'><span id='42499B08ED'></span></dt></select></label></b><u id='42499B08ED'></u>
          <i id='42499B08ED'><strike id='42499B08ED'><tt id='42499B08ED'><pre id='42499B08ED'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:673
          Mayo Clinic, in Rochester, Minnesota on
          Photo by KEREM YUCEL/AFP via Getty Images

          SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday.

          The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P. Morgan Healthcare Conference. Mayo and Cerebras did not disclose the dollar amount, but Cerebras said it was a multimillion, multi-year contract.

          advertisement

          With roughly 380 employees, Cerebras builds and sells supercomputers specifically designed for AI applications across several industries — pitting the upstart in direct competition with the market leader Nvidia Corp. Life sciences giants including GSK have used its technology for drug discovery, and it has partnered with a health network in United Arab Emirates, but this is Cerebras’ first AI contract with a U.S. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Wegovy trial has doctors encouraged over new possibilities
          Wegovy trial has doctors encouraged over new possibilities

          AdobeThemomentumaroundweightlossdrugsisabouttogetevenbiggerinthewakeofNovoNordisk’sannouncementthati

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Wegovy trial has doctors encouraged over new possibilities

          AdobeThemomentumaroundweightlossdrugsisabouttogetevenbiggerinthewakeofNovoNordisk’sannouncementthati